KR20210139259A - 면역조절 중간엽 줄기 세포 - Google Patents

면역조절 중간엽 줄기 세포 Download PDF

Info

Publication number
KR20210139259A
KR20210139259A KR1020217029168A KR20217029168A KR20210139259A KR 20210139259 A KR20210139259 A KR 20210139259A KR 1020217029168 A KR1020217029168 A KR 1020217029168A KR 20217029168 A KR20217029168 A KR 20217029168A KR 20210139259 A KR20210139259 A KR 20210139259A
Authority
KR
South Korea
Prior art keywords
mscs
cell
cells
pbmcs
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217029168A
Other languages
English (en)
Korean (ko)
Inventor
잔 스파스
사라 브룩스
Original Assignee
글로벌 스템 셀 테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글로벌 스템 셀 테크놀로지 filed Critical 글로벌 스템 셀 테크놀로지
Publication of KR20210139259A publication Critical patent/KR20210139259A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/03—Compounds acting on the NO pathway, e.g. nitrososarginine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020217029168A 2019-03-12 2020-03-12 면역조절 중간엽 줄기 세포 Ceased KR20210139259A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19162270 2019-03-12
EP19162270.3 2019-03-12
PCT/EP2020/056625 WO2020182935A1 (en) 2019-03-12 2020-03-12 Immunomodulating mesenchymal stem cells

Publications (1)

Publication Number Publication Date
KR20210139259A true KR20210139259A (ko) 2021-11-22

Family

ID=65801891

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217029168A Ceased KR20210139259A (ko) 2019-03-12 2020-03-12 면역조절 중간엽 줄기 세포

Country Status (10)

Country Link
US (2) US20220154147A1 (https=)
EP (1) EP3938494A1 (https=)
JP (1) JP7572367B2 (https=)
KR (1) KR20210139259A (https=)
CN (1) CN113677789B (https=)
AU (1) AU2020235912A1 (https=)
BR (1) BR112021017738A8 (https=)
CA (1) CA3132414A1 (https=)
MX (1) MX2021010739A (https=)
WO (1) WO2020182935A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146787A4 (en) 2020-05-08 2024-06-26 Gallant Pet, Inc. Uterine-derived regenerative cell compositions and uses thereof
WO2023280835A1 (en) 2021-07-08 2023-01-12 Boehringer Ingelheim Veterinary Medicine Belgium Mesenchymal stem cells for use in the treatment of chronic gingivostomatitis
CN117897165A (zh) 2021-07-08 2024-04-16 勃林格殷格翰比利时兽医公司 用于治疗特应性皮炎的间充质干细胞
US20230022259A1 (en) 2021-07-08 2023-01-26 Boehringer Ingelheim Veterinary Medicine Belgium Mesenchymal stem cells for use in the treatment of osteoarthritis in animals
CN117915924A (zh) 2021-07-08 2024-04-19 勃林格殷格翰比利时兽医公司 间充质干细胞用于治疗慢性肾病
AU2023323861A1 (en) 2022-08-11 2025-02-27 Boehringer Ingelheim Vetmedica Gmbh Mesenchymal stem cells for use in the treatment of insect-bite hypersensitivity in equines
WO2024133886A1 (en) * 2022-12-23 2024-06-27 Boehringer Ingelheim Veterinary Medicine Belgium Primed mesenchymal stem cells for use in the treatment of chronic kidney disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU755888B2 (en) 1998-03-18 2003-01-02 Mesoblast International Sarl Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
EP2298864B1 (en) 2004-03-22 2017-10-11 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US20140017787A1 (en) 2010-10-11 2014-01-16 Aline M. Betancourt Mesenchymal stem cells and related therapies
ITRM20110403A1 (it) * 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
KR102246369B1 (ko) * 2011-11-30 2021-04-29 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
WO2017160986A1 (en) 2016-03-16 2017-09-21 Cell Medicine, Inc. Mesenchymal stem cells with enhanced efficacy
US20220333197A1 (en) * 2019-01-31 2022-10-20 Primegen Biotech, Llc Treatment of Atopic Dermatitis Using Mesenchymal Stem Cells and Immune Modulation

Also Published As

Publication number Publication date
CN113677789A (zh) 2021-11-19
BR112021017738A8 (pt) 2022-08-02
EP3938494A1 (en) 2022-01-19
JP2022524764A (ja) 2022-05-10
US20250122477A1 (en) 2025-04-17
US20220154147A1 (en) 2022-05-19
CA3132414A1 (en) 2020-09-17
JP7572367B2 (ja) 2024-10-23
BR112021017738A2 (https=) 2021-11-16
CN113677789B (zh) 2024-11-01
WO2020182935A1 (en) 2020-09-17
MX2021010739A (es) 2021-12-15
AU2020235912A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US20250122477A1 (en) Immunomodulating mesenchymal stem cells
Tirino et al. Methods for the identification, characterization and banking of human DPSCs: current strategies and perspectives
Fazzina et al. Potency testing of mesenchymal stromal cell growth expanded in human platelet lysate from different human tissues
US20170121685A1 (en) Mesenchymal stem cell-derived exosomes and their uses
US11564948B2 (en) Therapeutic methods using erythrocytes
US20150329827A1 (en) Muse cells isolation and expansion
US20220218758A1 (en) Quadri-positive stromal cell (qpsc) population for superior cell protection and immunomodulation
Abdelhamid et al. Retinoic acid-mediated anti-inflammatory responses in equine immune cells stimulated by LPS and allogeneic mesenchymal stem cells
KR20170010894A (ko) 림프구로부터의 다계열 분화능 세포 생성 방법
CN117660320A (zh) 一种间充质干细胞cd317+亚群及其制备和其应用
WO2023216799A1 (zh) 一种人nkt细胞系及其应用
CA2767970C (en) Method for using directing cells for specific stem/progenitor cell activation and differentiation
US12173315B2 (en) Growth and survival compositions for cells capable of producing antibodies and methods related thereto
JP2021058165A (ja) 濾胞性制御性ｔ細胞の製造方法
KR20130056782A (ko) 말과동물 양막-유래 중간엽 줄기세포
RU2828728C2 (ru) Иммуномодулирующие мезенхимальные стволовые клетки
CN104995295A (zh) 多分化潜能细胞的制造方法
US20220169979A1 (en) Methods for enriching populations of cells
KR102011634B1 (ko) 향상된 산후 부착형 세포 및 그의 용도
Pereira Equine Endothelial Colony-Forming Cells: Phenotypic Enhancement and Ex vivo Angiogenesis Studies
CN110628715B (zh) 体外扩增自然杀手细胞及自然杀手t细胞的方法及其医药组成物
TWI669399B (zh) 體外擴增自然殺手細胞及自然殺手ｔ細胞之方法及其醫藥組成物
Mora Pereira Equine Endothelial Colony-Forming Cells: Phenotypic Enhancement and Ex vivo Angiogenesis Studies
US20150157663A1 (en) Pharmaceutical Composition Comprising Human-Blood-Derived-Cell Mass
TWI669400B (zh) 用於體外擴增自然殺手細胞及自然殺手ｔ細胞之無血清細胞培養液

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601